Valneva SE (VALN), a specialty vaccine company, Thursday reported net loss of 12.2 million euros for the full year, significantly lower than 101.4 million euros loss in the previous year, primarily helped by proceeds from the Priority Review Voucher (PRV) sale.
Adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization was 32.9 million euros compared with 65.2 million euros loss last year.
Revenue for the year grew 10 percent to 169.6 million euros from 153.7 million euros in the previous year.
Product sales increased 13 percent year-on-year to 163.3 million euros.
For fiscal 2025, the company expects product sales to be in the range of 170 million euros to 180 million euros and total revenue are expected between 180 million euros and 190 million euros.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.